---
title: "Adverse Events | Kisqali®"
description: "Discover the most common adverse events observed with KISQALI in combination with ET, including neutropenia, liver-related events, nausea, and QT prolongation."
canonical_url: "https://www.kisqali.com/advanced-breast-cancer/safety-data/adverse-events"
meta:
"og:description": "Discover the most common adverse events observed with KISQALI in combination with ET, including neutropenia, liver-related events, nausea, and QT prolongation."
"og:title": "Adverse Events"
---
## **Adverse events**
### **Majority of adverse reactions were manageable and mostly reversible. **(1,2)
- Neutropenia
Onset of neutropenia generally occurred within 17 days and were reversible with dose interruption, dose reduction or discontinuation. (1)
*Icon representing blood cells with two key stats: 20–33% of patients on KISQALI required dose reductions due to neutropenia; only 0.8% discontinued treatment.*
20–33%20 to 33%
required dose
reductions(1)
**0.8%**
needed to
discontinue treatment(2)
- Hepatobiliary toxicity
Onset of grade 3 and 4 AST/ALT elevations generally occurred within 3 months and resolved within a median of 21 days. (2)
*Liver icon with exclamation mark indicating hepatotoxicity: 12.3% of patients had dose interruptions or adjustments; 0.3% discontinued due to hepatotoxicity, 2.4% due to abnormal LFTs.*
**12.3%**
required dose interruptions or adjustments
**0.3%**
needed to discontinue treatment due to hepatotoxicity,
2,4% due to abnormal LFTs
\* To normalisation or grade ≤2 (2)
- QTcF prolongation
Onset of QTcF prolongation generally occurred within 15 days and were reversible with dose interruption and/or dose reduction. (2)
*Icon of a patient with a heartbeat line representing QTc prolongation: 2.9% of patients required dose interruptions or reductions; fewer than 1% discontinued treatment due to this effect.*
**2.9%**
required dose interruptions or reductions(1)
**<1%**
needed to discontinue treatment(2)
## Sitemap
See the full [sitemap](/sitemap.md) for all pages.